先天免疫系统
免疫疗法
肿瘤微环境
TLR4型
癌症研究
生物
免疫系统
细胞生物学
信号转导
免疫学
作者
Xiaoguang Li,Zhida Liu,Anli Zhang,Chuanhui Han,Aijun Shen,Lingxiang Jiang,David A. Boothman,Jian Qiao,Yang Wang,Xiumei Huang,Yang‐Xin Fu
标识
DOI:10.1038/s41467-019-11238-1
摘要
Abstract Lack of proper innate sensing inside tumor microenvironment (TME) limits T cell-targeted immunotherapy. NAD(P)H:quinone oxidoreductase 1 (NQO1) is highly enriched in multiple tumor types and has emerged as a promising target for direct tumor-killing. Here, we demonstrate that NQO1-targeting prodrug β-lapachone triggers tumor-selective innate sensing leading to T cell-dependent tumor control. β-Lapachone is catalyzed and bioactivated by NQO1 to generate ROS in NQO1 high tumor cells triggering oxidative stress and release of the damage signals for innate sensing. β-Lapachone-induced high mobility group box 1 (HMGB1) release activates the host TLR4/MyD88/type I interferon pathway and Batf3 dendritic cell-dependent cross-priming to bridge innate and adaptive immune responses against the tumor. Furthermore, targeting NQO1 is very potent to trigger innate sensing for T cell re-activation to overcome checkpoint blockade resistance in well-established tumors. Our study reveals that targeting NQO1 potently triggers innate sensing within TME that synergizes with immunotherapy to overcome adaptive resistance.
科研通智能强力驱动
Strongly Powered by AbleSci AI